Phillip Rappold, MD
Urology · Rochester, NYNPI 1265859185
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $12,750 of the $20,253 with a category attached, or 63.0%. Urogen Pharma, Inc. accounts for 80.2% of it on its own, with 1 other manufacturer making up the rest.
Across 22 payments — averaging $920.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Urogen Pharma, Inc.$16K
- Histosonics, Inc.$4K
Across 1 payment — averaging $82,834 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Histosonics, Inc.$83K
What the payments were for
- Consulting fees$2,25011%
- Speaking & faculty fees$12,75063%
- Travel & lodging$4,72623%
- Food & beverage$5263%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Urogen Pharma, Inc. | 18 | $16,250 |
| Histosonics, Inc. | 4 | $4,003 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JELMYTO$16,070
How this compares
$20,253 in reported general payments places this provider in the 85th percentile of 952 urology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 24 | $12,993 |
| Mirabegron ErMirabegron | 11 | $4,126 |
| Tamsulosin Hcl | 162 | $1,560 |
| Oxybutynin Chloride ErOxybutynin Chloride | 60 | $746 |
| Trospium Chloride | 14 | $431 |
| Finasteride | 21 | $235 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 13 | $157 |
| Cephalexin | 16 | $85 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 20 | $62 |
| Lorazepam | 12 | $7 |
Paid to pharmacies, not to this prescriber.
Other urology in Rochester
- Ahmed GhaziRochester$71K
- Peter WalterJamestown$1.9M
- Christopher PieczonkaSyracuse$797K
- Bilal ChughtaiNew York$658K
- Katie MurrayNew York$575K
- Neil BanderNew York$544K
- Robert ValenzuelaNew York$494K
- Jeffrey SpencerCheektowaga$430K
- Kyrollis AttallaNew York$381K
- Benjamin BruckerNew York$364K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.